ISSAR Pharmaceuticals Pvt. Ltd. Information

ISSAR’S purpose lies in the development of new technologies at an affordable price to improve quality of life for Indian population. With over 25 years of experience and prime focus in Research and Development, ISSAR’S dedicated team of experts are proud to have developed India’s first ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR’S commitment has also led to the development of their second New Chemical Entity called Xylentra®, which is the first ever peptide drug in the world for the treatment of burn wounds and microbial infections.Recently, ISSAR has also developed molecules for prevalent conditions in the Western world such as Inflammatory Bowel Diseases (IBD), Psoriasis and Sepsis. The future holds an extensive place for peptides as safe and efficient therapeutics with excellent diagnostic, preventive and curative properties. ISSAR is the only pharmaceutical company working as a purely peptide manufacturing technology based company with an FDA- compliant state-of-the-art manufacturing facility of 62000 sq. ft. located in Genome valley, Hyderabad, India. In addition to its experience in R&D, ISSAR is equipped with the most advanced and automated technology for synthesis and purification of peptides, producing highest standards of purity of up to 99.5% by continued process optimization. ISSAR uses Solid phase peptide synthesis as the technology of choice with a long-standing expertise in custom peptide synthesis at all scales. With our emphasis on quality, safety and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology and diseases of bones and joints.